IBOV 168,498.45 ▲ 1.39% IPC MEX 71,393.57 ▲ 0.43% MERVAL 2,848,945 — — USD/BRL5.51▲ 0.02% USD/MXN18.60▼ 0.16% USD/CLP 975.74 — 0.00% USD/COP3,238▼ 0.08% USD/PEN3.43▼ 0.25% USD/ARS1,545▼ 0.03% USD/UYU40.31— 0.00% USD/PYG 6,358 — 0.00% USD/BOB 11.81 — 0.00% USD/DOP60.63▲ 0.07% USD/CRC 448.27 — 0.00% USD/GTQ 7.64 — 0.00% USD/HNL26.88— 0.00% USD/NIO 36.62 — 0.00% USD/VES895.29▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.83— 0.00% USD/TTD6.72— 0.00% EUR/BRL6.15▲ 0.40% BRENT 96.30 ▼ 2.05% WTI 89.55 ▼ 1.41% IRON ORE 161.91 — — COPPER 6.31 ▲ 1.42% GOLD 4,103 ▲ 0.69% SILVER 52.34 ▲ 1.04% SOY 1,195 ▲ 0.48% CORN 441.75 ▲ 0.06% WHEAT 587.50 ▼ 0.63% COFFEE 280.15 ▲ 1.08% SUGAR 18.25 ▼ 1.67% ORANGE JUICE 130.55 ▲ 1.63% COTTON 78.54 ▼ 0.22% COCOA 5,119 ▼ 1.20% BEEF 214.05 ▼ 0.16% CATTLE 318.38 ▼ 2.05% LITHIUM 60.91 ▲ 1.21% PETR4 45.36 — 0.00% VALE3 64.04 — 0.00% ITUB4 40.53 — 0.00% BBDC4 14.20 — 0.00% ABEV3 15.48 — 0.00% BBAS3 17.13 — 0.00% B3SA3 14.39 — 0.00% WEGE3 48.19 — 0.00% PRIO3 60.48 — 0.00% SUZB3 53.40 ▲ 2.12% RENT3 30.29 — 0.00% AZZA3 14.76 ▲ 4.98% CSAN3 2.77 — 0.00% RAIZ4 28.00 ▲ 2.56% PCAR3 2.40 ▲ 0.42% GMAT3 3.80 — 0.00% PSSA3 44.35 ▲ 1.46% CVCB3 0.84 ▲ 2.44% POSI3 3.09 ▼ 0.64% SLCE3 16.61 ▲ 1.59% NATU3 5.17 — 0.00% BRKM5 3.20 — 0.00% RANI3 8.53 ▲ 0.83% CSNA3 4.41 — 0.00% IBOV 168,498.45 ▲ 1.39% IPC MEX 71,393.57 ▲ 0.43% MERVAL 2,848,945 — — USD/BRL 5.51 ▲ 0.02% USD/MXN 18.61 ▼ 0.10% USD/CLP 975.74 — 0.00% USD/COP 3,238 ▼ 0.08% USD/PEN 3.43 ▼ 0.35% USD/ARS 1,545 ▼ 0.03% USD/UYU 40.31 ▲ 3.23% USD/PYG 6,358 — 0.00% USD/BOB 11.81 — 0.00% USD/DOP 60.63 ▲ 0.07% USD/CRC 448.27 — 0.00% USD/GTQ 7.64 — 0.00% USD/HNL 26.88 ▲ 3.19% USD/NIO 36.62 — 0.00% USD/VES 895.29 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.83 ▲ 2.67% USD/TTD 6.72 ▲ 2.44% EUR/BRL 6.15 ▲ 0.40% BRENT 96.30 ▼ 2.05% WTI 89.55 ▼ 1.41% IRON ORE 161.91 — — COPPER 6.31 ▲ 1.42% GOLD 4,103 ▲ 0.69% SILVER 52.34 ▲ 1.04% SOY 1,195 ▲ 0.48% CORN 441.75 ▲ 0.06% WHEAT 587.50 ▼ 0.63% COFFEE 280.15 ▲ 1.08% SUGAR 18.25 ▼ 1.67% ORANGE JUICE 130.55 ▲ 1.63% COTTON 78.54 ▼ 0.22% COCOA 5,119 ▼ 1.20% BEEF 214.05 ▼ 0.16% CATTLE 318.38 ▼ 2.05% LITHIUM 60.91 ▲ 1.21% PETR4 45.36 — 0.00% VALE3 64.04 — 0.00% ITUB4 40.53 — 0.00% BBDC4 14.20 — 0.00% ABEV3 15.48 — 0.00% BBAS3 17.13 — 0.00% B3SA3 14.39 — 0.00% WEGE3 48.19 — 0.00% PRIO3 60.48 — 0.00% SUZB3 53.40 ▲ 2.12% RENT3 30.29 — 0.00% AZZA3 14.76 ▲ 4.98% CSAN3 2.77 — 0.00% RAIZ4 28.00 ▲ 2.56% PCAR3 2.40 ▲ 0.42% GMAT3 3.80 — 0.00% PSSA3 44.35 ▲ 1.46% CVCB3 0.84 ▲ 2.44% POSI3 3.09 ▼ 0.64% SLCE3 16.61 ▲ 1.59% NATU3 5.17 — 0.00% BRKM5 3.20 — 0.00% RANI3 8.53 ▲ 0.83% CSNA3 4.41 — 0.00%
since 2009
Monday, November 9, 2026

Latest News Brazil

Researchers Discover Promising New Treatment Against Covid-19

By · · 2 min read

RIO DE JANEIRO, BRAZIL – A combination of the antivirals interferon beta-1b, lopinavir-ritonavir (a medicine used against the HIV virus), and ribavirin (often used in hepatitis C cases) may be a promising treatment against the novel coronavirus.

This is the result of research conducted by six hospitals in Hong Kong and published in the renowned scientific journal The Lancet. The study considered only mild and moderate cases of the virus.

2
A cocktail of antivirals was tested only in mild and moderate cases of coronavirus.
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

To conduct the study, 127 patients, with an average age of 52 years, were divided into two groups. The first group, with 86 people, was administered the complete cocktail, and, on average, seven days after the start of treatment the virus spread was reduced, while the second group, a control group, consisted of 41 people, treated only with lopinavir-ritonavir. The reduction of the virus in the second case took longer, twelve days.

The triple combination also yielded good results in the patient discharge time: the first group was discharged in nine days, and the second in up to 14.5 days. When treated with the cocktail, the symptoms also disappeared faster and in four days people already saw an improvement in their cases. Those using the lopinavir-ritonavir alone saw their symptoms disappear in double the time.

A third phase of the research will still be conducted, according to the researchers. “The next phase with interferon-beta 1b and a third placebo group should be considered because comparisons between the subgroups have shown that interferon beta-1b is a key component in our combination treatment. The lack of patients in a severe condition has not allowed the findings to be generalized to more severe cases,” explains the study.

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “Paraguay's Senate ousts its president after a bank failure”

Free. We send a confirmation link first — nothing arrives until you click it. Unsubscribe with one click in any edition. If you stop opening us for 30 days we stop sending by ourselves, as we assume the interest is no longer there. See our privacy policy. We never share your email.

The randomized clinical study (when subjects are randomly assigned to two or more intervention groups) was conducted directly with humans and enjoys high reliability among the scientific community.

Source: Exame

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.